



Issuer Hansa Biopharma AB

Holder

Braidwell LP

Instrument

Instrument Shares

Before the transaction

Shares 1,038,210
Voting rights 1,038,210

Transaction

Reason for major shareholding notification New share issue
Date 12/04/2024
Limit for number of shares 5 %
Limit for number of votes 5 %

After the transaction

Quantity

Shares 6,112,950
Directly held voting rights 6,112,950
Indirectly held voting rights 0

Percentage

Directly held shares 9.33147 %
Directly held voting rights 9.6445 %
Indirectly held voting rights 0 %

Resulting distribution of total holdings

	Percentage of voting rights:	Number of underlying shares:
Shares	9.6445 %	6,112,950

Instruments - FITA Ch. 4, section 2, first paragraph, line 2

Instruments - FITA Ch. 4, section 2, first paragraph, line 3

- Physically settled
- Cash settled

Total 9.6445 % 6,112,950

Group total holdings

Voting rights 6,112,950
Percentage of voting rights 9.6445

Notes (other relevant informations according to law)

Braidwell LP (the "Shareholder") has participated in the directed share issue in Hansa Biopharma (the "Issuer") announced by the Issuer on 12 April 2024 by way of press release. The directed share issue is split into two tranches and the Shareholder has acquired 6,112,950 new ordinary shares delivered to the Shareholder in the first tranche, resulting in the Shareholder's percentage of total number of shares increasing to 9.33147% and percentage of total number of votes increasing to 9.64450%. The shareholding is calculated based on the total number of shares (65,508,981) and votes(63,382,780.50) in the Issuer after the first tranche of the directed share issue.

Published

17/04/2024 14:47

Contact

Name Manish Mital
Phone +1 (203) 694-3275 Email compliance@braidwell.com

CLOSE PRINT